Metagenomi TherapeuticsMGX +3.31%10 Market Cap is $46.87 Mil as of Jun. 28, 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,429 Biotechnology companies, Metagenomi Therapeutics ranks worse than 64.24% on this metric.
Metagenomi Therapeutics's quarterly market cap
declined
from Sep. 2025 ($88.99 Mil) to Dec. 2025 ($60.95 Mil) and
declined
from Dec. 2025 ($60.95 Mil) to Mar. 2026 ($50.45 Mil).
Metagenomi Therapeutics's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($135.08 Mil) but then
declined
from Dec. 2024 ($135.08 Mil) to Dec. 2025 ($60.95 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Metagenomi Therapeutics's Enterprise Value for Today is $-54.11 Mil.
Metagenomi Therapeutics (NAS:MGX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Metagenomi Therapeutics Market Cap Related Terms
Metagenomi Therapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Metagenomi Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Metagenomi Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a Market Cap of $46.87 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Metagenomi Therapeutics and its competitors. According to the industry distribution chart, Metagenomi Therapeutics ranks #918 out of 1429 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Metagenomi Therapeutics' Market Cap too high?
Metagenomi Therapeutics' current Market Cap is $46.87 Mil. The Biotechnology industry median Market Cap is 112.70. Metagenomi Therapeutics' value of $46.87 Mil is 58.4% below this industry median. Based on the distribution chart, Metagenomi Therapeutics ranks #918 out of 1429 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Market Cap compare to HYPD and ATYR?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #918 out of 1429 companies for Market Cap. This places Metagenomi Therapeutics in the lower half of its industry. The industry median Market Cap is 112.70. Metagenomi Therapeutics' value of $46.87 Mil is 58.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metagenomi Therapeutics's current Market Cap of $46.87 Mil is 58.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Metagenomi Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metagenomi Therapeutics's current Market Cap is $46.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Market Cap of $46.87 Mil. The current Market Cap is $46.87 Mil and 58.4% below the Biotechnology industry median of 112.70. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Market Cap is $46.87 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
